Capricor Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Capricor (CAPR)
Capricor investors lost 60% to 70% after FDA briefing documents challenged the Company's claims that Deramiocel demonstrated statistically significant benefits. NEW YORK, July 29, 2026 /PRNewswire/ -- Capricor (NASDAQ: CAPR) investors were hit with a 60% to 70% drop on July 27, 2026,...
Capricor investors lost 60% to 70% after FDA briefing documents challenged the Company's claims that Deramiocel demonstrated statistically significant benefits. NEW YORK, July 29, 2026 /PRNewswire/ -- Capricor (NASDAQ: CAPR) investors were hit with a 60% to 70% drop on July 27, 2026,...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.